A novel lncRNA RP11-544M22.13 enhances glycolysis-induced cisplatin resistance in non-small cell lung cancer.

ABSTRACT: LncRNAs and glycolysis play integral roles in the advancement and development of different types of cancer, such as non-small cell lung cancer (NSCLC). This particular study aims to delve into the specific function and potential mechanism of RP11-544M22.13, a newly identified lncRNA, in NSCLC. We utilized qRT-PCR to measure RP11-544M22.13, miR-1291, and SLC2A1 expression levels. The MTT assay assessed NSCLC cell chemoresistance. RP11-544M22.13 was highly elevated in diamminedichloroplatinum (DDP)-resistant NSCLC tissues and cells, promoting both DDP resistance and malignant behavior. Its mechanism involved targeting SLC2A1, suppressing miR-1291, and subsequently upregulating SLC2A1 expression via direct interaction with SLC2A1 mRNA. RP11-544M22.13 acts as a miR-1291 sponge, boosting SLC2A1 expression and promoting DDP resistance and malignancy in NSCLC cells. This presents a potential treatment target for NSCLC and aids in developing small-molecule drugs for combined chemotherapy in late-stage, chemoresistant NSCLC patients.

SUBMITTER: Xiong J 

PROVIDER: S-EPMC12808317 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature